Ifn γ brilliant violet 711 4s b3

Manufactured by BioLegend

IFN-γ Brilliant Violet 711 (4S.B3) is a fluorochrome-conjugated antibody used to detect and quantify interferon-gamma (IFN-γ) expression in biological samples. The antibody is conjugated with Brilliant Violet 711, a fluorescent dye that can be excited by a violet laser and detected in the appropriate channel.

Automatically generated - may contain errors

Lab products found in correlation

Tnf α pe, by BD (2 mentions) Summit data acquisition and analysis software, by Agilent Technologies (2 mentions) Streptavidin pacific blue, by Thermo Fisher Scientific (2 mentions) Ifn γ apc 4s b3, by BD (2 mentions) Cd49d 9f10, by BD (2 mentions) Cd4 bv510 l200, by BD (2 mentions) Perforin biotinylated pf 344, by Mabtech (2 mentions) Tnf α pe cy7, by BD (2 mentions) Cd3 pb sp34 2, by BD (1 mentions) Cd8 pb rpa t8, by BD (1 mentions) Ebio64cap17, by Thermo Fisher Scientific (1 mentions) Lsrfortessa cell analyzer, by BD (1 mentions) Cd8 pacificblue rpa t8, by BD (1 mentions) Cd3 pacific blue sp34 2, by BD (1 mentions)

Close spelling variants of this product

IFN-γ (4S.B3), Brilliant Violet 711 IFN-γ

2 protocols using ifn γ brilliant violet 711 4s b3

Flow Cytometry Antibody Staining Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols

The following antibodies were used for culturing or surface and intracellular cytokine staining (ICS) for flow cytometry: CD28 (CD28.2, BD), CD49d (9F10, BD), CD3-PB (SP34-2, BD), CD4-BV510 (L200, BD), CD8-PB (RPA-T8, BD), IFN-γ-APC (4S.B3, BD), IFN-γ Brilliant Violet 711 (4S.B3, Biolegend), TNF-α-PE (MAb11, BD), TNF-α-PE-Cy7 (MAb11, BD), IL-17-PE (eBio64CAP17, eBioscience), IL-22-biotinylated (anti-human IL-22, RD), Streptavidin-Pacific blue (Invitrogen), Perforin-biotinylated (Pf-344, Mabtech), Caspase 3-AF647 (C92-605,BD), and anti-Vγ2-FITC (7A5, Pierce).
After staining, the cells were fixed and subjected to flow cytometry. Lymphocytes were gated based on forward- and side-scatters, and at least 40,000 gated events were analyzed using Summit Data Acquisition and Analysis Software (DakoCytomation).

Yang E., Yang R., Guo M., Huang D., Wang W., Zhang Z., Chen C., Wang F., Ho W., Shen L., Xiao H., Chen Z.W, & Shen H. (2018). Multidrug-resistant tuberculosis (MDR-TB) strain infection in macaques results in high bacilli burdens in airways, driving broad innate/adaptive immune responses. Emerging Microbes & Infections, 7, 207.

+ Open protocol

+ Expand

Cytokine Analysis by Flow Cytometry

Check if the same lab product or an alternative is used in the 5 most similar protocols

The following Abs were used for culture or surface and intracellular cytokine staining for flow cytometry: CD28 (CD28.2, BD), CD49d (9F10, BD), CD3-Pacific blue (SP34-2,BD), CD4-BV510 (L200, BD), CD8- Pacific blue (RPA-T8, BD), IFN-γ-APC (4S.B3, BD), IFN-γ Brilliant Violet 711 (4S.B3, Biolegend), TNF-α-PE (Mab11, BD), TNF-α-PE-Cy7 (Mab11, BD), IL-17-PE (eBio64CAP17, eBioscience), IL-22-biotinylated (anti-human IL-22, RD), Streptavidin-Pacific blue (invitrogen), Perforin-biotinylated (Pf-344, Mabtech), Caspase 3-AF647 (C92-605,BD), anti-Vγ2-FITC (7A5, Pierce).
After staining, cells were fixed and subjected to analysis on flow cytometer of BD LSRFortessa^TM Cell Analyzer. Lymphocytes were gated based on forward- and side-scatters, and at least 40,000 gated events were analyzed using Summit Data Acquisition and Analysis Software (Dako Cytomation).

Shen H., Yang E., Guo M., Yang R., Huang G., Peng Y., Sha W., Wang F, & Shen L. (2022). Adjunctive Zoledronate + IL-2 administrations enhance anti-tuberculosis Vγ2Vδ2 T-effector populations, and improve treatment outcome of multidrug-resistant tuberculosis1. Emerging Microbes & Infections, 11(1), 1790-1805.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!